Physix Frontier badgePhysix Frontier
PublishChinese | EN

Physix Frontier · News Briefing Card (IT Home · Oct 8, 2026)

Isomorphic Labs eyes new round at $40B-$50B valuation

KEY FACTS

  • Isomorphic Labs is in early talks for a new funding round.
  • The company is led by Demis Hassabis, winner of the 2024 Nobel Prize in Chemistry.
  • Isomorphic Labs is Alphabet's AI drug discovery company.
  • The company closed a Series B round in May this year, raising $2.1 billion.
  • The new round values the company at no less than $40 billion, and potentially as much as $50 billion.

KEY DATA

$40 billionNew round valuation floor
$50 billionNew round valuation ceiling
$2.1 billionSeries B raise

PHYSIX OBSERVATION

AI drug discovery is still in its early days, yet Isomorphic has landed a valuation close to that of mature pharma companies, showing that capital is betting on the platform and the Nobel-winning team, not on a pipeline already on the market. The signal: the valuation logic for AI pharma is shifting from pipeline progress to model capability, but the clinical translation risk has not fallen as a result.

Source: IT Home report

Isomorphic Labs eyes new round at $40B-$50B valuation | Physix Frontier Briefing